Respiratory syncytial virus and parainfluenza virus

New England Journal of Medicine

Volumn 344, Issue 25, 2001, Pages 1917-1928

  Hall, C B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; NONHUMAN; PARAINFLUENZA VIRUS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS CHARACTERIZATION; VIRUS INFECTION; VIRUS ISOLATION;

ASTHMA; CROUP; HUMANS; IMMUNOCOMPROMISED HOST; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 2, HUMAN; PARAINFLUENZA VIRUS 3, HUMAN; RECURRENCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RESPIROVIRUS INFECTIONS; RUBULAVIRUS INFECTIONS; VIRAL VACCINES;

EID: 0035927982     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106213442507     Document Type: Review

References (99)

1. Recovery of cytopathogenic agent from chimpanzees with coryza
2. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization
3. Impact of respiratory virus infections on persons with chronic underlying conditions
4. The prospects for immunizing against respiratory syncytial virus
5. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children
6. RSV pneumonia, a community-acquired infection in adults
7. Acute respiratory tract infection in daycare centers for older persons
8. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults
9. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990
10. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection
11. Respiratory syncytial virus
12. Parainfluenza viruses
13. Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: Analysis of 12 clinical isolates
14. Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages
15. Update: Respiratory syncytial virus activity - United States, 1997-1998 season
16. Occurrence of groups A and B of respiratory syncytial virus over 15 years: Associated epidemiologic and clinical characteristics in hospitalized and ambulatory children
17. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community
18. Parainfluenza virus type 4 infections in pediatric patients
19. Respiratory syncytial virus infections in adults: Clinical, virologic, and serial pulmonary function studies
20. Infectivity of respiratory syncytial virus by various routes of inoculation
21. Modes of transmission of respiratory syncytial virus
22. Possible transmission by fomites of respiratory syncytial virus
23. Survival and disinfection of parainfluenza viruses on environmental surfaces
24. Respiratory syncytial virus
25. Bronchiolitis-associated hospitalizations among US children, 1980-1996
26. Economic evaluation of respiratory syncytial virus infection in Canadian children: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study
27. Morbidity associated with the major respiratory viruses
28. Parainfluenza viral infections in pediatric outpatients: Seasonal patterns and clinical characteristics
29. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old
30. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion
31. Pediatric hospitalizations for croup (laryngotracheobronchitis): Biennial increases associated with human parainfluenza virus 1 epidemics
32. Role of respiratory viruses in exacerbations of primary nephrotic syndrome
33. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: A review of the PICNIC RSV database
34. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis
35. Severe viral respiratory infections in infants with cystic fibrosis
36. Prevalencia de síntomas relacionados con el asma en niños de 13-14 años de 9 poblaciones españolas
37. An estimate of the prevalence of asthma and wheezing among inner-city children
38. Asthma and wheezing in the first six years of life
39. Infections prevent the development of asthma - True, false, or both?
40. Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis
41. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood
42. The incidence of respiratory tract infection in adults requiring hospitalization for asthma
43. Respiratory viruses and exacerbations of asthma in adults
44. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children
45. Immunologic mechanisms of virus-induced wheezing and asthma
46. Neural control mechanisms within airways: Disruption by respiratory syncytial virus
47. Respiratory syncytial virus infections in immunocompromised adults
48. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host
49. Orthomyxoviral and paramyxoviral infections in transplant patients
50. Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward
51. Respiratory syncytial viral infection in children with compromised immune function
52. Alterations in apoptosis of cord and adult peripheral blood mononuclear cells induced by in vitro infection with respiratory syncytial virus
53. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients
54. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients
55. Community respiratory viruses in individuals with human immunodeficiency virus infection
56. Respiratory-syncytial-virus infections, reinfections and immunity
57. Risk of primary infection and reinfection with respiratory syncytial virus
58. Parainfluenza virus type 3: Seasonality and risk of infection and reinfection in young children
59. Immunity to and frequency of reinfection with respiratory syncytial virus
60. Respiratory syncytial virus infections within families
61. Acute viral infections of upper respiratory tract in elderly people living in the community: Comparative, prospective, population based study of disease burden
62. An outbreak of an influenza-like illness in a nursing home
63. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly
64. Respiratory syncytial virus and influenza A infections in the hospitalized elderly
65. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease
66. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population
67. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: An aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
68. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
69. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
70. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine
71. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection
72. Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and effective immunization
73. Protective and disease-enhancing immune responses to respiratory syncytial virus
74. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults
75. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
76. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
77. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
78. Culture vs direct antigen assays for detection of microbial pathogens from lower respiratory tract specimens suspected of containing the respiratory syncytial virus
79. Rapid simultaneous diagnosis of infections with respiratory syncytial virus A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex)
80. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults
81. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old
82. Maternal immunization against viral disease
83. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
84. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children
85. Evaluation of a live, attenuated respiratory syncytial virus (RSV) vaccine candidate, cpts 248/404, in infancy
86. Evaluation of live recombinant RSV A2 vaccines in children over 6 months of age
87. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
88. Respiratory syncytial virus vaccines
89. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: Memorandum from a joint WHO/NIAID meeting
90. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants
91. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
92. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV
93. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children
94. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
95. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants
96. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - A compassionate use experience
97. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity
98. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection
99. First International Symposium on Influenza and other Respiratory Viruses: Summary and overview: Kapalua, Maui, Hawaii, December 4-6, 1998